

James O'donnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7328619/publications.pdf>

Version: 2024-02-01

144
papers

6,414
citations

81743

39
h-index

74018

75
g-index

144
all docs

144
docs citations

144
times ranked

8250
citing authors

#	ARTICLE	IF	CITATIONS
1	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. <i>Blood Advances</i> , 2023, 7, 302-308.	2.5	3
2	Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance. <i>Haematologica</i> , 2022, 107, 668-679.	1.7	8
3	Examining international practices in the management of pregnant women with von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 82-91.	1.9	7
4	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 62-71.	2.5	17
5	Persistent endotheliopathy in the pathogenesis of long COVID syndrome –Reply to comment from von Meijenfeldt et al.. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 270-271.	1.9	5
6	Therapeutic implications of ongoing alveolar viral replication in COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e135-e144.	2.2	17
7	Practical treatment guidance for cancer-associated thrombosis – Managing the challenging patient: A consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103599.	2.0	6
8	The von Willebrand factor – ADAMTS13 axis in malaria. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12641.	1.0	5
9	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 3735-3745.	2.5	3
10	Nanoparticle Biomolecular Corona-Based Enrichment of Plasma Glycoproteins for N-Glycan Profiling and Application in Biomarker Discovery. <i>ACS Nano</i> , 2022, 16, 5463-5475.	7.3	17
11	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. <i>Haematologica</i> , 2022, 107, 1950-1954.	1.7	3
12	Perspective: The Case for Acute Large Vessel Ischemic Stroke in COVID-19 Originating Within Thrombosed Pulmonary Venules. <i>Stroke</i> , 2022, 53, 2411-2419.	1.0	3
13	von Willebrand disease and von Willebrand factor. <i>Haemophilia</i> , 2022, 28, 11-17.	1.0	3
14	Neutrophils in COVID-19: Not Innocent Bystanders. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	52
15	Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2350-2365.	1.9	18
16	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 701-710.	1.9	7
17	von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli. <i>Thrombosis and Haemostasis</i> , 2021, 121, 086-097.	1.8	2
18	Rapid Whole Blood Clot Retraction Assay on Quartz Crystal Microbalance. , 2021, 5, 1-4.		1

#	ARTICLE	IF	CITATIONS
19	Heterogeneity in Bleeding Tendency and Arthropathy Development in Individuals with Hemophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 183-191.	1.5	3
20	Toward Personalized Treatment for Patients with Low von Willebrand Factor and Quantitative von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 192-200.	1.5	2
21	Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1064-1070.	1.9	142
22	Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort. <i>Haemophilia</i> , 2021, 27, 618-625.	1.0	9
23	Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. <i>Intensive Care Medicine</i> , 2021, 47, 899-902.	3.9	38
24	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinicopathological entity with heterogeneous clinical presentations. <i>British Journal of Haematology</i> , 2021, 195, 76-84.	1.2	42
25	The Biological Significance of von Willebrand Factor O-Linked Glycosylation. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 855-861.	1.5	10
26	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1914-1921.	1.9	58
27	Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12531.	1.0	18
28	Illustrated State of the Art Capsules of the ISTH 2021 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12532.	1.0	2
29	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3536.	1.0	5
30	Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2738-2743.	1.9	9
31	How I treat bleeding disorder of unknown cause. <i>Blood</i> , 2021, 138, 1795-1804.	0.6	18
32	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2546-2553.	1.9	208
33	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. <i>Blood Advances</i> , 2021, 5, 5023-5031.	2.5	6
34	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 280-300.	2.5	246
35	Correcting dominant-negative von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 55-57.	1.9	1
36	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. <i>British Journal of Haematology</i> , 2021, 192, 714-719.	1.2	92

#	ARTICLE	IF	CITATIONS
37	Recombinant factor IXâ€ƒ fusion protein in severe hemophilia B: Patientâ€ƒreported outcomes and healthâ€ƒrelated quality of life. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12602.	1.0	4
38	Single centre, realâ€ƒworld experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. <i>Haemophilia</i> , 2021, 27, e690-e697.	1.0	7
39	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	2.5	5
40	An international survey to inform priorities for new guidelines on von Willebrand disease. <i>Haemophilia</i> , 2020, 26, 106-116.	1.0	32
41	Telehealth for delivery of haemophilia comprehensive care during the COVIDâ€ƒ19 pandemic. <i>Haemophilia</i> , 2020, 26, 984-990.	1.0	31
42	Pulmonary intravascular coagulopathy in COVID-19 pneumonia â€ƒ Authors' reply. <i>Lancet Rheumatology</i> , The, 2020, 2, e460-e461.	2.2	14
43	Low VWF: insights into pathogenesis, diagnosis, and clinical management. <i>Blood Advances</i> , 2020, 4, 3191-3199.	2.5	22
44	Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria. <i>Blood Advances</i> , 2020, 4, 2851-2864.	2.5	25
45	The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. <i>Blood</i> , 2020, 136, 2864-2874.	0.6	75
46	Expresser phenotype determines ABO(H) blood group antigen loading on platelets and von Willebrand factor. <i>Scientific Reports</i> , 2020, 10, 18366.	1.6	3
47	More on â€ƒAssociation between ABO blood groups and risk of SARSâ€ƒCoVâ€ƒ2 pneumoniaâ€ƒ™. <i>British Journal of Haematology</i> , 2020, 190, 27-28.	1.2	35
48	Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. <i>Lancet Rheumatology</i> , The, 2020, 2, e437-e445.	2.2	652
49	New developments in von Willebrand disease. <i>British Journal of Haematology</i> , 2020, 191, 329-339.	1.2	27
50	More on COVIDâ€ƒ19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020, 189, 1060-1061.	1.2	73
51	Apolipoprotein A-I enhances activated protein C cytoprotective activity. <i>Blood Advances</i> , 2020, 4, 2404-2408.	2.5	7
52	Investigating the clearance of VWF Aâ€ƒdomains using siteâ€ƒdirected PEGylation and novel Nâ€ƒlinked glycosylation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1278-1290.	1.9	8
53	Endothelial cells orchestrate COVID-19 coagulopathy. <i>Lancet Haematology</i> , the, 2020, 7, e553-e555.	2.2	122
54	Biological mechanisms underlying interâ€ƒindividual variation in factor VIII clearance in haemophilia. <i>Haemophilia</i> , 2020, 26, 575-583.	1.0	29

#	ARTICLE	IF	CITATIONS
55	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	1.2	307
56	Antithrombin inhibition using nanobodies to correct bleeding in hemophilia. EMBO Molecular Medicine, 2020, 12, e12143.	3.3	3
57	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 431-497.	1.0	11
58	Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone. Journal of Thrombosis and Haemostasis, 2019, 17, 426-428.	1.9	0
59	von Willebrand factor promotes wound healing. Blood, 2019, 133, 2553-2555.	0.6	2
60	von Willebrand factor sialylation - A critical regulator of biological function. Journal of Thrombosis and Haemostasis, 2019, 17, 1018-1029.	1.9	30
61	Advances in understanding the molecular mechanisms of venous thrombosis. British Journal of Haematology, 2019, 186, 13-23.	1.2	31
62	Advances in understanding the molecular mechanisms that maintain normal haemostasis. British Journal of Haematology, 2019, 186, 24-36.	1.2	46
63	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
64	Perioperative management of patients with von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 604-609.	0.9	14
65	How I treat low von Willebrand factor levels. Blood, 2019, 133, 795-804.	0.6	36
66	Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function. Blood, 2019, 133, 1371-1377.	0.6	36
67	Management of combined factor V and factor VIII deficiency in pregnancy. Journal of Obstetrics and Gynaecology, 2019, 39, 271-272.	0.4	4
68	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood, 2018, 131, 911-916.	0.6	54
69	The Immunoregulatory Activities of Activated Protein C in Inflammatory Disease. Seminars in Thrombosis and Hemostasis, 2018, 44, 167-175.	1.5	10
70	A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy. Haemophilia, 2018, 24, e22-e25.	1.0	7
71	Emerging Roles for von Willebrand Factor in Cancer Cell Biology. Seminars in Thrombosis and Hemostasis, 2018, 44, 159-166.	1.5	34
72	Platelets in malaria pathogenesis. Blood, 2018, 132, 1222-1224.	0.6	12

#	ARTICLE	IF	CITATIONS
73	von Willebrand factor clearance – biological mechanisms and clinical significance. <i>British Journal of Haematology</i> , 2018, 183, 185-195.	1.2	51
74	Significant gynecological bleeding in women with low von Willebrand factor levels. <i>Blood Advances</i> , 2018, 2, 1784-1791.	2.5	79
75	Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1223-1223.	0.6	1
76	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1–A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 845-855.	1.1	29
77	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. <i>Blood</i> , 2017, 130, 2344-2353.	0.6	98
78	Targeting von Willebrand Factor–Mediated Inflammation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1590-1591.	1.1	16
79	Microbiome influences von Willebrand factor. <i>Blood</i> , 2017, 130, 393-395.	0.6	3
80	Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters. <i>Thrombosis</i> , 2016, 2016, 1-3.	1.4	5
81	X-linked moyamoya syndrome associated with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, e51-e54.	1.0	12
82	New treatment approaches to von Willebrand disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 683-689.	0.9	27
83	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 855-863.	1.1	23
84	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. <i>Blood</i> , 2016, 127, 1192-1201.	0.6	41
85	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. <i>Blood</i> , 2016, 128, 1959-1968.	0.6	31
86	Emerging roles for hemostatic dysfunction in malaria pathogenesis. <i>Blood</i> , 2016, 127, 2281-2288.	0.6	54
87	N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2446-2457.	1.9	27
88	Measurement of the viscoelastic properties of blood plasma clot formation in response to tissue factor concentration-dependent activation. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6581-6588.	1.9	14
89	Recurrent lower limb venous thrombosis associated with a congenitally absent infrarenal inferior vena cava. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 57-57.	0.2	1
90	Engineering activated protein C to maximize therapeutic efficacy. <i>Biochemical Society Transactions</i> , 2015, 43, 691-695.	1.6	12

#	ARTICLE	IF	CITATIONS
91	Activated protein C β 2-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. <i>Blood</i> , 2015, 126, 915-919.	0.6	20
92	Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. <i>Haemophilia</i> , 2015, 21, e498-e500.	1.0	5
93	von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 821-826.	1.9	28
94	Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells. <i>Haematologica</i> , 2014, 99, 185-193.	1.7	22
95	The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Directors Organization guideline approved by the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , 2014, 167, 453-465.	1.2	297
96	A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. <i>Analyst</i> , The, 2013, 138, 4769.	1.7	23
97	Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities. <i>Blood</i> , 2013, 121, 3801-3810.	0.6	63
98	Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. <i>Blood</i> , 2013, 122, 4107-4110.	0.6	65
99	A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care. <i>Proceedings of SPIE</i> , 2013, , .	0.8	0
100	Clinical utility gene card for: haemophilia B. <i>European Journal of Human Genetics</i> , 2012, 20, 3-3.	1.4	2
101	Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 98-103.	0.5	1
102	Oral Rivaroxaban for Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 2525-2527.	13.9	2
103	Elevated plasma factor VIII levels in patients with venous thrombosis – Constitutional risk factor or secondary epiphenomenon?. <i>Thrombosis Research</i> , 2012, 129, 105-106.	0.8	5
104	Elevated factor VIII levels and risk of venous thrombosis. <i>British Journal of Haematology</i> , 2012, 157, 653-663.	1.2	236
105	The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 717-726.	2.4	49
106	Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. <i>Thrombosis Research</i> , 2011, 128, e125-e129.	0.8	4
107	Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. <i>Thrombosis Research</i> , 2011, 128, e166-e170.	0.8	3
108	Clinical utility gene card for: von Willebrand disease. <i>European Journal of Human Genetics</i> , 2011, 19, 615-615.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 56, 992-997.	1.4	1
110	Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 399, 691-700.	1.9	6
111	Activated Protein C N-Linked Glycans Modulate Cytoprotective Signaling Function on Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 1323-1330.	1.6	30
112	Clinical utility gene card for: Haemophilia A. <i>European Journal of Human Genetics</i> , 2011, 19, 1-3.	1.4	32
113	Rapid activation of endothelial cells enables <i>Plasmodium falciparum</i> adhesion to platelet-decorated von Willebrand factor strings. <i>Blood</i> , 2010, 115, 1472-1474.	0.6	112
114	Expression of terminal α 2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13. <i>Blood</i> , 2010, 115, 2666-2673.	0.6	79
115	Platelet von Willebrand factor α structure, function and biological importance. <i>British Journal of Haematology</i> , 2010, 148, 834-843.	1.2	69
116	Review: Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. <i>Palliative Medicine</i> , 2010, 24, 386-395.	1.3	22
117	Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins. <i>Talanta</i> , 2010, 81, 1725-1730.	2.9	16
118	Platelet Factor 4 Impairs the Anticoagulant Activity of Activated Protein C. <i>Journal of Biological Chemistry</i> , 2009, 284, 5869-5875.	1.6	23
119	Severe <i>Plasmodium falciparum</i> Malaria Is Associated with Circulating Ultra-Large von Willebrand Multimers and ADAMTS13 Inhibition. <i>PLoS Pathogens</i> , 2009, 5, e1000349.	2.1	105
120	The protein C α 1-loop substitution Asn21Ile is associated with reduced protein C anticoagulant activity. <i>British Journal of Haematology</i> , 2009, 144, 946-953.	1.2	13
121	Does antithrombotic therapy improve survival in cancer patients?. <i>Blood Reviews</i> , 2009, 23, 129-135.	2.8	26
122	Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. <i>Blood</i> , 2009, 114, 1658-1665.	0.6	113
123	Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. <i>Thrombosis and Haemostasis</i> , 2008, 99, 570-575.	1.8	28
124	Dissociation of Activated Protein C Functions by Elimination of Protein S Cofactor Enhancement. <i>Journal of Biological Chemistry</i> , 2008, 283, 30531-30539.	1.6	38
125	Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 689-692.	0.5	32
126	ABO Blood Group Phenotypes and <i>Plasmodium falciparum</i> Malaria: Unlocking a Pivotal Mechanism. <i>Advances in Parasitology</i> , 2007, 65, 1-50.	1.4	56

#	ARTICLE	IF	CITATIONS
127	Antithrombin Nagasaki (Ser 116 to Pro): a rare antithrombin variant with abnormal heparin binding presenting during pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 217-220.	0.5	0
128	ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. <i>Transfusion</i> , 2006, 46, 1836-1844.	0.8	343
129	von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. <i>British Journal of Haematology</i> , 2006, 133, 562-569.	1.2	116
130	Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 465-468.	0.5	24
131	Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. <i>Blood</i> , 2005, 105, 1085-1093.	0.6	217
132	Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. <i>Blood</i> , 2005, 106, 1988-1991.	0.6	99
133	Role of the Thrombelastograph as an adjunctive test in thrombophilia screening. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 207-211.	0.5	38
134	Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. <i>British Journal of Haematology</i> , 2003, 121, 928-931.	1.2	7
135	Acquired protein s deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange. <i>British Journal of Haematology</i> , 2003, 122, 518-519.	1.2	11
136	Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. <i>British Journal of Haematology</i> , 2003, 123, 139-141.	1.2	6
137	Title is missing!. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 283-287.	0.5	10
138	Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 1591-1598.	0.9	2
139	Amount of HAntigen Expressed on Circulating von Willebrand Factor Is Modified by ABO Blood Group Genotype and Is a Major Determinant of Plasma von Willebrand Factor Antigen Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 335-341.	1.1	125
140	Genotype at the Secretor blood group locus is a determinant of plasma von Willebrand factor level. <i>British Journal of Haematology</i> , 2002, 116, 350-356.	1.2	45
141	A Tyr346→Cys substitution in the interdomain acidic region 1 of factor VIII in an individual with factor VIII:C assay discrepancy. <i>British Journal of Haematology</i> , 2002, 118, 589-594.	1.2	46
142	Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. <i>British Journal of Haematology</i> , 2001, 115, 687-691.	1.2	51
143	Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. <i>British Journal of Haematology</i> , 2000, 110, 454-460.	1.2	192
144	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	5